Dyne Therapeutics, Inc. $DYN Shares Bought by Moore Capital Management LP

Key Points

• Moore Capital Management increased its Dyne Therapeutics position by 288.2% in the second quarter, holding 305,794 shares valued at approximately $6.8 million. Institutional investors and hedge funds collectively own 96.68% of the company.
• Insider activity was mixed: Director Jason P. Rhodes sold 2.16 million shares for about $54.0 million under a Rule 10b5-1 plan, while Director Brian S. Posner bought 2,500 shares. Insiders have sold roughly $99.4 million of stock over the past 90 days.
• Dyne reported a quarterly loss of $1.08 per share, below the $0.75 consensus estimate. Analysts nevertheless maintain a “Moderate Buy” consensus, with an average price target of $34.42 versus the stock’s recent price near $25.07.

Moore Capital Management LP raised its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 288.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 305,794 shares of the company's stock after buying an additional 227,029 shares during the period. Moore Capital Management LP owned about 0.16% of Dyne Therapeutics worth $6,792,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of the company. Hilton Head Capital Partners LLC purchased a new position in Dyne Therapeutics during the 1st quarter valued at about $26,000. Strs Ohio purchased a new position in Dyne Therapeutics in the 4th quarter valued at approximately $51,000. Allworth Financial LP acquired a new position in shares of Dyne Therapeutics in the second quarter worth $62,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Dyne Therapeutics during the fourth quarter worth $84,000. Finally, Steward Partners Investment Advisory LLC raised its stake in shares of Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company's stock valued at $95,000 after acquiring an additional 2,465 shares in the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Jason P. Rhodes sold 2,160,516 shares of the company's stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the completion of the sale, the director owned 428,946 shares in the company, valued at $10,723,650. This represents a 83.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Brian S. Posner bought 2,500 shares of Dyne Therapeutics stock in a transaction dated Wednesday, June 3rd. The stock was purchased at an average price of $17.48 per share, with a total value of $43,700.00. Following the purchase, the director directly owned 22,500 shares in the company, valued at approximately $393,300. This trade represents a 12.50% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have sold 4,139,196 shares of company stock worth $99,449,852. Insiders own 9.46% of the company's stock.

Dyne Therapeutics Stock Performance

Shares of Dyne Therapeutics stock opened at $25.07 on Monday. The company has a quick ratio of 12.02, a current ratio of 12.02 and a debt-to-equity ratio of 0.28. Dyne Therapeutics, Inc. has a 52 week low of $11.92 and a 52 week high of $27.31. The firm's 50 day moving average is $24.37 and its two-hundred day moving average is $20.08. The firm has a market capitalization of $4.68 billion, a P/E ratio of -7.53 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.33). Research analysts forecast that Dyne Therapeutics, Inc. will post -3.47 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on DYN shares. Weiss Ratings restated a "sell (d-)" rating on shares of Dyne Therapeutics in a report on Friday, July 17th. Cantor Fitzgerald assumed coverage on Dyne Therapeutics in a research report on Thursday, July 23rd. They set an "overweight" rating for the company. TD Cowen assumed coverage on shares of Dyne Therapeutics in a research note on Friday, June 26th. They set a "buy" rating on the stock. Sanford C. Bernstein raised their target price on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a "market perform" rating in a report on Wednesday, May 13th. Finally, HC Wainwright reiterated a "buy" rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Monday, August 17th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Dyne Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $34.42.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source